New obesity drug candidate enters human safety testing

NCT ID NCT07716241

Not yet recruiting Disease control Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests an experimental drug called HS-20136-2, given as an injection under the skin, to see if it is safe and tolerable in healthy and obese adults aged 18 to 55. The trial also looks at how the drug moves through the body and whether it causes weight changes. Participants receive either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental injection called HS-20136-2
What this could lead to: If successful, this could lead to a new treatment option for obesity that helps with weight loss.
What could go wrong: This is an early Phase 1 trial focused on safety, so it is too soon to know if HS-20136-2 will be effective or have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The Second Hospital of Ahui Medical University

Hefei, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.